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Abstract
Utilizing a multi-parametric flow cytometry (MPFC) protocol, we assessed various cell-types 
implicated in tumor angiogenesis that were found circulating in the peripheral blood of children 
with sarcomas (cases) based on their cell surface antigen expression. Circulating endothelial cells 
(CECs), endothelial colony forming cells (ECFCs) and the ratio of two distinct populations of 
circulating hematopoietic stem and progenitor cells (CHSPCs), the pro-angiogenic CHSPCs 
(pCHSPCs) and non-angiogenic CHSPCs (nCHSPCs) were enumerated. MPFC was analyzed in 
cases at baseline and at 4 additional time-points until the end of treatment and levels compared 
with each other and with healthy controls. At all time-points, cases had significantly lower levels 
of CECs, but elevated ECFCs and a pCHSPC:nCHSPC ratio compared to controls (all p values 
<0.05). There was no significant difference in any of the cell types analyzed based on tumor-
histology, stage (localized v/s metastatic) or tumor-size. After treatment, only the CECs among the 
complete responders were significantly lower at end of therapy (p<0.01) compared to non-
responders, whereas the ECFCs among all cases significantly increased (p<0.05)) compared to 
baseline. No decline in the pCHSPC:nCHSPC ratio was observed despite tumor response. Based 
on these results, a validation of CECs as prognostic biomarker is now warranted.
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Introduction
All solid tumors, including pediatric malignancies, depend on angiogenesis for tumor 
growth, invasion and metastases.1-5 Therefore, targeted anti-angiogenic therapies are 
promising novel strategies that have recently emerged in the treatment of pediatric solid 
tumor patients with the goal of improving survival, particularly for those with metastatic or 
relapsed disease.3,6-12 However, lack of predictive biomarkers for gauging tumor response 
makes it difficult to ascertain which patients receiving these anti-angiogenic agents would 
respond and thereby benefit. This deficit makes it difficult to individualize therapies and 
exposes non-responders to treatments that are ineffective, and furthermore, may cause harm.
To address this issue, several groups have identified circulating endothelial progenitor cells 
(EPCs) as potential predictive biomarkers of response to anti-angiogenic agents. EPCs were 
first shown to contribute to vasculogenesis13 and subsequently to tumor induced 
angiogenesis.14 However, there has been a lack of consensus in defining EPCs leading to 
grouping various cell types under the umbrella of “EPC” and thus an inability to compare 
study results. Utilizing a novel multi-parametric flow cytometry (MPFC) protocol, our group 
has identified and defined the bona fide EPC, namely the endothelial colony forming cells 
(ECFCs) that are identified as CD31+CD34brightCD45-AC133-CD14-LIVE/DEAD- cells, 
that have high proliferative potential, and give rise to perfused blood vessels in vivo.15-18 In 
addition, we have also enumerated circulating endothelial cells (CECs) that are identified as 
CD31brightCD45-CD34dimAC133- cells and are mature, apoptotic endothelial cells sloughed 
off from the vessel wall during vascular remodeling and do not form perfused blood vessels 
in vivo. Finally, using MPFC we have identified two unique circulating hematopoietic stem 
and progenitor cell (CHSPC) populations in both peripheral blood and umbilical cord blood, 
which are phenotypically and functionally distinct from EPCs but are still actively involved 
in angiogenesis. These CHSPCs are vital for blood vessel formation in physiological and 
pathological states through their interactions with mature endothelial cells and ECFCs, and 
are further classified into 2 distinct cellular subsets based on both cell surface antigen 
expression and function.17,19 The parent CHSPC population which contains both fractions is 
defined by the expression of CD31+CD34brightCD45dimCD14-LIVE/DEAD- with the 
expression of AC133 the hallmark between the two subsets. The pro-angiogenic CHSPCs 
(pCHSPCs) express AC133, while the non-angiogenic CHSPCs (nCHSPCs) do not. The 
ratio of the pCHSPCs to nCHSPCs is a way to normalize the wide variability observed in 
the total number of CHSPCs, pCHSPCs, or nCHSPCs, with normal healthy ratios between 
1.2-1.8.17,19 An increased pCHSPC:nCHSPC ratio (>2.0) is associated with tumor induced 
angiogenesis.17,20-22
To validate CECs, ECFCs, and the pCHSPC:nCHSPC ratio as biomarkers of tumor induced 
angiogenesis, prognostic biomarkers to current treatment strategies and predictive 
biomarkers of targeted anti-angiogenic agents further studies are essential. The purpose of 
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our current pilot study, an initial step in that direction was to evaluate longitudinal 
measurements of the CECs, ECFCs, and the pCHSPC:nCHSPC ratio in pediatric sarcoma 
patients. In the development of the MPFC protocol, we determined that both fresh blood and 
blood processed and stained within 24 hours (utilizing BD Vacutainer CPT Cell preparation 
tubes) were similar in terms of cellular populations.17,19,22 Our first aim was to demonstrate 
the feasibility of performing the real time MPFC protocol in a multi-institutional setting. 
This step was necessary for planning future multi-institutional studies since reliability of this 
protocol depends upon timely analysis of the peripheral blood within 24 hours after 
collection, and involves the processing and shipping of peripheral blood samples to a 
centralized core facility to perform the MPFC staining, collection, and analysis. Our next 
objectives were to examine the relationship and differences between baseline tumor 
characteristics and CECs, ECFCs, and the pCHSPC:nCHSPC ratio. Finally, we evaluated 
the impact of cancer-directed therapies on CECs, ECFCs, and the pCHSPC:nCHSPC ratio in 
a prospective setting.
Materials and Methods
Peripheral Blood Collection
We conducted a longitudinal study at three academic children's hospitals in the United 
States (James Whitcomb Riley Hospital for Children [Indianapolis, IN], Ann and Robert H. 
Lurie Children's Hospital [Chicago, IL], and the University of Kentucky Children's Hospital 
[Lexington, KY]). This study was approved by the institutional review boards at each 
collaborative site. Children (1-21 years of age) with a diagnosis of Osteosarcoma (OS), 
Ewing's sarcoma (EWS), Rhabdomyosarcoma (RMS) or Undifferentiated sarcoma (US) 
were eligible for this study provided they had not received any prior cancer directed therapy 
other than a diagnostic biopsy. Patients with localized disease that was completely resected 
with no other metastatic lesions were not eligible for the study. Age-matched, healthy 
controls were enrolled for comparison.
Informed parental consents, and when appropriate, children's assents, were obtained prior to 
enrollment. Enrolled patients had placement of a vascular access through which baseline 
peripheral blood was obtained and sent for enumeration of CECs, ECFCs, and CHSPCs 
using MPFC as previously described.17,19,22 The CECs and ECFCs were expressed as 
percentage of the total circulating mononuclear cell (MNC) population. The 
pCHSPC:nCHSPC ratio was determined by the percentage of live MNCs that were pro-
angiogenic CHSPCs divided by the percentage of live MNCs that were non-angiogenic 
CHSPCs.
Since the MPFC assay was stained in real-time within 24 hours after peripheral blood 
collection at the Angio BioCore located at Indiana University, peripheral blood shipped 
from other clinics were processed by a defined standard operating procedure at site of 
collection and sent overnight via Federal Express for next morning delivery.
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Antibodies and Staining Reagents
The following primary conjugated monoclonal antibodies were used: anti-human CD31 
fluoroscein isothyocyanate (FITC, BD Pharmingen), anti-human CD34 phycoerythrin (PE, 
BD Pharmingen), anti-human AC133 allophycocyanin (APC, Miltenyi Biotec), anti-human 
CD14 PECy5.5 (Abcam), anti-human CD45 APC-AlexaFluor (AF) 750 (Invitrogen), and 
the fixable amine reactive viability dye, LiveDead (Violet, Invitrogen).
In order to resolve the rare and/or dim populations of interest, specific antigen and 
fluorochrome conjugate coupling was optimized for the five-antibody plus viability marker 
staining panel as previously described.17,19,22
Multi-Parametric Flow Cytometry Immunostaining, Acquisition and Analysis
Peripheral blood MNCs were incubated with Fc blocking reagent (Miltenyi Biotec) and 
stained as previously described. 17,19,22 “Fluorescent minus one” (FMO) gating controls 
were also used to ensure proper gating of positive events.17,19 Briefly, cells were incubated 
with titred antibodies for 30 minutes at 4°C, washed twice in PBS with 2% fetal bovine 
serum (FBS), fixed in 1% paraformaldehyde (Tousimis), and run within 72 hours of fixation 
on a BD LSRII flow cytometer (BD, Franklin Lakes, NJ, USA) equipped with a 405nm 
violet laser, 488nm blue laser and 633nm red laser. Data were acquired uncompensated and 
exported as FCS 3.0 files, and analyzed utilizing FlowJo software, version 9.7.2 (Tree Star, 
Inc).
Tumor Characteristics, Cancer-therapies and Response Assessment
Baseline tumor characteristics evaluated were tumor histology, size, and presence or absence 
of metastases as shown in Table 1. All patients were enrolled either on a therapeutic clinical 
protocol or a standard clinical treatment plan with cancer-directed therapies summarized in 
Table 2. CECs, ECFCs and CHSPCs were enumerated at diagnosis; after the first cycle of 
chemotherapy at least 24 hours after ending granulocyte colony stimulating factor (G-CSF); 
up to 24 hours before initiating treatment of the primary tumor site with surgery or radiation 
therapy (local control); after local control of the primary tumor site prior to initiation of 
adjuvant chemotherapy; and finally at the end of all planned treatment (after count 
recovery). The only significant difference between those who received G-CSF vs. those who 
did not was with respect to the underlying tumor-pathology (p=0.0006) as shown in Table-2. 
Response evaluations were recorded by radiographic (measurements in 2 dimensions using 
the product of width and length per the WHO criteria), clinical, and staging evaluations at 
the end of all planned therapies.
Statistical Analysis
Categorical variables were summarized by frequencies and percentages. Pearson's chi-
square tests were used for comparison between groups. Continuous variables were 
summarized by means and standard deviations (SDs). Normality was checked for each 
variable. When the normality assumption held, Student's t-tests were adopted for 
comparisons and Pearson's correlation coefficients were generated. When the normality 
assumption failed, Wilcoxon's signed rank tests and rank sum tests were used for 
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comparisons and Spearman's correlation coefficients were generated. Complete case 
approach was adopted for all the analyses.
Results
There were 31 Sarcoma patients enrolled as shown in Table 1 with 9 females and 22 males. 
The mean age was 11 years (SD=4.3). There was no significant difference of age and gender 
between cases and healthy controls. The control group had more females, however, the p-
value was not significant because of the small sample size. There were an equal number of 
cases with EWS and OS (n=12 each) and the rest were RMS or US. Twenty-one patients had 
metastatic disease of which 2 patients had complete resection of the primary tumor at 
diagnosis and 10 patients had localized disease at baseline staging work-up. The average 
tumor size was 52.72 cms2 (SD=52.99).
We next examined the tumor characteristics of size, stage and histology at baseline. As 
shown in Table 3, no significant correlations between tumor size and CECs, ECFCs, and the 
pCHSPC:nCHSPC ratio were found. In addition, there was no difference in CECs, ECFCs, 
and the pCHSPC:nCHSPC ratio based on tumor stage or histology (data shown for EWS 
and OS tumors only due to small sample size in RMS/US category).
The treatment summaries and response data for all evaluable cases is shown in Table 2. Two 
patients had progressive disease and were unable to complete their upfront planned 
treatment. Baseline CECs, ECFCs, and pCHSPC: nCHSPC ratio did not significantly 
correlate with response at the end of treatment. As shown in Figure 1 and Table 4, we 
examined the effects of therapy on CECs, ECFCs, and the pCHSPC:nCHSPC ratio.
The CECs were significantly lower at diagnosis and all subsequent treatment stages 
compared to healthy controls (Figure 1A; *p<0.001). There was no difference in CECs 
before and after local control. However, at the end of therapy all patients with a complete 
response had significantly lower levels of CECs (p=0.01) compared to those without a 
complete response. Lower levels of CECs in complete responders continued to be 
significantly lower than healthy controls (p<0.0001)
On the other hand, ECFCs were significantly elevated at diagnosis in all patients with 
tumors compared to the healthy controls (Figure 1B; *p=0.0021). After cycle-1 of 
chemotherapy the ECFCs significantly increased compared to diagnosis (p=0.036). There 
was no difference in the ECFCs before and after local control. All cases at end of therapy 
had significantly higher levels of ECFCs compared to levels at diagnosis (p=0.01) and cases 
who had a complete response at end of therapy also had significantly higher levels of ECFCs 
compared to levels at diagnosis (p=0.035). In addition, at the end of therapy all patients 
(responders and non-responders) had significantly elevated levels of ECFCs (Figure 1B; 
**p=0.0001) compared to healthy controls.
Finally, the pCHSPC:nCHSPC ratio was elevated at the time of diagnosis and at all 
treatment stages in all cases compared to healthy controls (Figure 1C; *all p values <0.05). 
There was no difference in the pCHSPC:nCHSPC ratio at any time-points during therapy, 
even when a therapeutic response was observed.
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Discussion
This is the first report demonstrating decreased CECs and increased ECFCs and a 
pCHSPC:nCHSPC ratio among pediatric sarcoma patients compared to age matched healthy 
controls. This study demonstrated the feasibility of conducting MPFC analysis in real-time. 
We found that the CECs, ECFCs, and the pCHSPC:nCHSPC ratio were not associated with 
tumor size, tumor stage, or histology. Furthermore, we found that the CECs were the only 
cell type that was significantly lower among patients with a complete response compared to 
those without. Interestingly, there were significantly higher levels of ECFCs among all 
patients at the end of therapy compared to diagnosis.
The pCHSPC:nCHSPC ratio was elevated in all patients regardless of therapeutic outcome. 
In patients with a complete response, we would have expected the pCHSPC:nCHSPC ratio 
to normalize at the end of treatment. However, there was no significant difference in the 
pCHSPC:nCHSPC ratio at the time of diagnosis versus at the end of therapy even in the 
complete responders. It is possible that this ratio takes more time to normalize to that 
observed in healthy controls. It is also possible that the use of G-CSF, a known 
hematopoietic cell mobilizer, increased the level of pCHSPCs in the peripheral circulation.
Our previous observations of an increased pCHSPC:nCHSPC ratio in pediatric solid tumor 
patients compared to healthy controls was confirmed in this study.22 These results are 
similar to several adult studies with varying solid and hematopoietic malignancies that 
revealed elevated levels of circulating endothelial and progenitor cells. 23-26 These 
progenitor cells, particularly the AC133+ pCHSPCs, secrete angiogenic factors such as 
VEGF and RANTES, and thereby stimulate the growth and viability of endothelial and 
cancer cells. 21 We recently demonstrated in a novel dual humanized bone marrow 
melanoma xenograft model that an increase in the pCHSPC:nCHSPC ratio in the peripheral 
blood correlated with increased growth of human melanoma xenografts.21 Studies are 
currently in progress to fully define the homing and requirement of the pCHSPCs in solid 
tumor growth using additional dually humanized bone marrow tumor xenograft models 
including, glioblastoma in situ. Additionally, in vitro studies showed a pro-angiogenic 
cytokine profile from the conditioned media of pCHSPCs, and an increase in the tube 
formation of ECFCs when co-cultured, thus further indicating the pro-angiogenic capacity 
of the pCHSPCs.21 Therefore, the significantly elevated pCHSPC:nCHSPC ratio among our 
patient population compared to controls is consistent with the hypothesis that pediatric 
malignant tumors are nurtured by the pro-angiogenic effects of the pCHSPCs for tumor 
growth.
In contrast to Taylor et al.,1 who showed higher levels of circulating vascular endothelial 
growth factor receptor 2+ (VEGFR-2+) bone marrow derived progenitor cells in the 
peripheral blood of pediatric solid tumor patients with metastatic disease, we did not find 
any significant differences in the levels of CECs, ECFCS or the pCHSPC:nCHSPC ratio 
based on tumor stage. This observation may be due to the differences in tumor types studied, 
but more importantly, it may be explained by the lack of consensus regarding the phenotypic 
definition of circulating progenitor cell subsets that are relevant in tumor induced 
angiogenesis. Most previous studies utilized CD34, AC133/CD133, and VEGFR-2/Kinase 
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insert domain receptor (KDR) or any combinations of these cell surface antigens to quantify 
both hematopoietic and endothelial progenitor cells, therefore making comparisons between 
various clinical studies impossible.18,27 In addition to the lack of consensus on phenotypic 
definition and corresponding functional data to prove the identity of these cells, the inability 
to accurately titrate commercially available KDR antibodies has caused further confusion 
about the use of it as a cell-surface cytometry marker.19 Additionally, in a previously 
published study of OS patients, circulating endothelial cells and endothelial progenitor cells 
were not elevated and also did not correlate with OS tumor size, stage, or response to 
therapy compared to controls.28 The phenotypic enumeration of circulating endothelial 
progenitor cells in that study involved CD146+, CD31+, CD45-, and CD133+ cells. 
However, the true EPCs (i.e. ECFCs) are AC133-15, so this difference in phenotypic 
expression may explain the difference in elevations of endothelial progenitor cells between 
our studies.
We did not find any significant correlations between baseline CECs, ECFCs, and the 
pCHSPC:nCHSPC ratio and tumor response. This may be due to small sample size in our 
pilot study. Interestingly, we encountered no decline in the pCHSPC:nCHSPC ratio 
following treatment compared to levels at the time of diagnosis. We also found a significant 
increase in ECFCs at the end of treatment when compared to baseline levels. Both the 
ECFCs and the pCHSPC:nCHSPC ratio continued to be significantly elevated at each time 
point when compared to controls. This persistent elevation may be attributed to rapid bone 
marrow mobilization of progenitor cells following chemotherapy and/or the use of G-CSF, 
as has been shown in pre-clinical studies. 29-31 Additional studies have also confirmed bone 
marrow mobilization of hematopoietic stem and progenitor cells as a result of tissue injury 
and during tissue repair. 32-34 This finding may explain the lack of difference in the ECFCs 
and the pCHSPC:nCHSPC ratio in our patients before and after local control since all 
patients had tissue injury following surgery and/or radiotherapy of their primary tumor site.
These findings have significant implications to change the paradigm of chemotherapy 
administration in sarcoma patients. Studies have shown that bone marrow mobilized cells 
can home towards viable tumor sites and promote angiogenesis off-setting the anti-tumor 
responses of conventional cancer therapies. 30,31 Potentially, these stimulatory signals could 
be disrupted by anti-angiogenic agents, thereby sensitizing the anti-tumor effects of 
chemotherapeutic agents. Therefore, the timing of administration of anti-angiogenic agents 
to block the stimulatory signals of both the pCHSPCs and ECFCs released as a result of 
conventional cancer therapies might be as important as the choice of the agent. This strategy 
warrants additional pre-clinical investigations using humanized xenograft models. 
Measurement of the CECs, pCHSPCS:nCHSPC ratio, and ECFCs in real time could 
therefore aid in optimal administration of chemotherapy agents that can be personalized to 
individual patients. Although no novel anti-angiogenic agent was used in our study, future 
studies are being planned that will focus on measuring the CECs, ECFCs and the 
pCHSPC:nCHSPC ratio in patients getting only targeted anti-angiogenic agents such as in 
Phase-1 studies where mobilization effects on these progenitor cells as seen with 
conventional therapies would be minimal. The significant decrease in CECs, especially 
among patients with a complete response compared to those without a complete response, 
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needs further pre-clinical investigation to identify the role of the apoptotic mature 
endothelial cells in the successful remission of solid tumors.
In conclusion, this is the first multi-center pilot study highlighting the feasibility of a novel 
MPFC protocol to detect circulating cells involved in tumor angiogenesis in pediatric 
sarcoma patients. In this study we have confirmed our previous findings that sarcoma 
patients have elevated levels of endothelial and hematopoietic stem and progenitor cells 
associated with tumor angiogenesis. Although the study was not powered to validate these 
cells as prognostic biomarkers of tumor response, there was a significant decline in CECs 
among those with a complete response compared to non-responders. Validating the CECs, 
ECFCs and the pCHSPC:nCHSPC ratio as prognostic biomarkers will require statistically 
powered clinical trials and longer follow-up times.
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Figure 1. CECs, ECFCs and the pCHSPC:nCHSPC ratio for patients with cancer at different 
treatment stages and the control group
CECs in patients were significantly lower at baseline and all subsequent treatment stages 
compared to healthy controls (A; *p=0.01). ECFCs were significantly elevated at baseline in 
all patients compared to the controls (B; *p=0.010). At the end of therapy all patients 
(responders and non-responders) had significantly elevated ECFCs (B; **p<0.05)) 
compared to healthy controls, and baseline. The pCHSPC:nCHSPC ratio was elevated at 
baseline and at all treatment stages in all cases compared to controls (C; *p<0.01).
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Table 1
Patient Characteristics at Baseline
Cases N=31 Control Group N=21 p value
Female 9 (29.03%) 11 (52.38%) 0.09
Age (years) 11.23 (4.30) 11.24 (4.02) 0.99
Tumor Histology Ewing's Sarcoma 12 (38.71%)
Osteosarcoma 12 (38.71%)
Rhabdomyosarcoma 5 (16.13%)
Undifferentiated Sarcoma 2 (6.45%)
Tumor Stage Local 21 (67.74%)
Metastatic 10 (32.25%)
Tumor Size (width × length) (cm2) 52.72 (52.99)
Categorical variables are displayed as frequency (%). Continuous variables are displayed as mean (SD)
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Table 2
Treatment Summary and Response of all Evaluable Cases
Cancer-directed Therapy and Response EWS (n=12) OS (n=12) RMS/US (n=5)
Chemotherapy Regimens VAdriaC; IE Cisplat/Adria; HD-MTX VAC; Ifos/Adria
Surgery for Local Control 4/12 = 33% 12/12 = 100% 1/5 =20%
Radiation for Local Control 9/12 = 75% 1/12 = 8.3% 4/5 = 80%
G-CSF Support 12/12 = 100% 4/12 = 33% 2/5 = 40%
Complete Response 8/12 = 66% 9/12 = 75% 1/5 = 20%
EWS: Ewing's sarcoma; OS: Osteosarcoma; RMS/US: Rhabdomyosarcoma and Undifferentiated sarcoma; VAdriaC: Vincristine, Doxorubicin, 
Cyclophosphamide; IE: Ifosfamide and Etoposide; Cisplat/Adria: Cisplatin and Doxorubicin; HD-MTX: high-dose Methotrexate; VAC: 
Vincristine, Actinomycin-D and Cyclophosphamide; Ifos/Adria: Ifosfamide and Doxorubicin; G-CSF: Granulocyte Colony Stimulating Factor.
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Table 3
Tumor Characteristics at Baseline, CECs, ECFCs and the pCHSPC:nCHSPC Ratio
CECs ECFCs pCHSPC:nCHSPC ratio
Tumor size (n=29) Spearman correlation -0.22 -0.22 0.13
p value* 0.27 0.27 0.53
Metastatic vs Local Mean (SD) difference -0.0003 (0.0022) -0.0042 (0.0232) -0.31 (1.19)
p value* 0.60 0.46 0.76
EWS vs. OS Mean (SD) difference -0.0004 (0.0020) 0.0027 (0.0069) 0.47 (1.26)
p value* 0.06 0.25 0.65
EWS: Ewing's sarcoma; OS: Osteosarcoma; CECs: Circulating Endothelial Cells; ECFCs; Endothelial Colony Forming Cells; pCHSPC:nCHSPC 
ratio: Ratio of Pro-angiogenic Circulating Hematopoietic Stem and Progenitor Cells to Non-angiogenic Circulating Hematopoietic Stem and 
Progenitor Cells.
*p values are from Wilcoxon rank sum tests, for the normality assumptions do not hold.
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Table 4
Comparisons of CECs, ECFCs and the pCHSPC:nCHSPC ratio for the cases with cancer 
at different treatment time points and with the healthy control group
Group CECs ECFCs pCHSPC:nCHSPC ratio
Healthy Control 0.16 (0.25) 0.00096 (0.00097) 1.25 (0.20)
Cases, Baseline (n=29) 0.00099 (0.0022) 0.0090 (0.023) 2.13 (1.18)
Cases, After Cycle 1 (n=26) 0.0020 (0.0040) 0.0084 (0.0088) ⱡ 3.40 (4.99)
Cases, Pre-local Control (n=22) 0.0014 (0.0026) 0.0057 (0.0065) 3.14 (5.56)
Cases, Post-local Control (n=27) 0.0029 (0.00057) 0.0076 (0.0073) 1.95 (1.35)
Cases, End of Therapy (n=20) 0.00049 (0.0010) 0.031 (0.076) ⱡ 2.10 (1.51)
Cases, End of TherapyComplete Response (n=15) 0.00015 (0.00043)* 0.035 (0.087) 2.16 (1.65)
CECs: Circulating Endothelial Cells; ECFCs; Endothelial Colony Forming Cells; pCHSPC:nCHSPC ratio: Ratio of Pro-angiogenic Circulating 
Hematopoietic Stem and Progenitor Cells to Non-angiogenic Circulating Hematopoietic Stem and Progenitor Cells.
Results presented as mean (SD).For the cases, all biomarkers at all treatment stages are significantly different from the healthy control group. 
(p<0.05)
ⱡSignificantly different from the baseline values after Cycle-1 (p=0.036) and at end of treatment (p=0.010)
*Significantly different from those without a complete-response (p=0.01)
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